{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:50:23Z","timestamp":1791399023104,"version":"4.3.3"},"reference-count":35,"publisher":"American Society of Hematology","issue":"9","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,29]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>CD20 is an established therapeutic target in B-cell malignancies. The CD20\u00a0\u00d7 CD3 bispecific antibody mosunetuzumab has significant efficacy in B-cell non-Hodgkin lymphomas (NHLs). Because target antigen loss is a recognized mechanism of resistance, we evaluated CD20 expression relative to clinical response in patients with relapsed and\/or refractory NHL in the phase 1\/2 GO29781 trial investigating mosunetuzumab monotherapy. CD20 was studied using immunohistochemistry (IHC), RNA sequencing, and whole-exome sequencing performed centrally in biopsy specimens collected before treatment at predose, during treatment, or upon progression. Before treatment, most patients exhibited a high proportion of tumor cells expressing CD20; however, in 16 of 293 patients (5.5%) the proportion was &amp;lt;10%. Analyses of paired biopsy specimens from patients on treatment revealed that CD20 levels were maintained in 29 of 30 patients (97%) vs at progression, where CD20 loss was observed in 11 of 32 patients (34%). Reduced transcription or acquisition of truncating mutations explained most but not all cases of CD20 loss. In\u00a0vitro modeling confirmed the effects of CD20 variants identified in clinical samples on reduction of CD20 expression and missense mutations in the extracellular domain that could block mosunetuzumab binding. This study expands the knowledge about the occurrence of target antigen loss after anti-CD20 therapeutics to include CD20-targeting bispecific antibodies and elucidates mechanisms of reduced CD20 expression at disease progression that may be generalizable to other anti-CD20 targeting agents. These results also confirm the utility of readily available IHC staining for CD20 as a tool to inform clinical decisions. This trial was registered at www.ClinicalTrials.gov as #NCT02500407.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023022348","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T18:01:35Z","timestamp":1701712895000},"page":"822-832","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":86,"title":["Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas"],"prefix":"10.1182","volume":"143","author":[{"given":"Stephen J.","family":"Schuster","sequence":"first","affiliation":[{"name":"1Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Yuh","family":"Huw","sequence":"additional","affiliation":[{"name":"2Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Bolen","sequence":"additional","affiliation":[{"name":"2Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Maximov","sequence":"additional","affiliation":[{"name":"2Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Polson","sequence":"additional","affiliation":[{"name":"2Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2670-0307","authenticated-orcid":false,"given":"Katerina","family":"Hatzi","sequence":"additional","affiliation":[{"name":"2Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth A.","family":"Lasater","sequence":"additional","affiliation":[{"name":"2Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit E.","family":"Assouline","sequence":"additional","affiliation":[{"name":"3Jewish General Hospital, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-394X","authenticated-orcid":false,"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"4Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"L. Elizabeth","family":"Budde","sequence":"additional","affiliation":[{"name":"5City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-3721","authenticated-orcid":false,"given":"Matthew J.","family":"Matasar","sequence":"additional","affiliation":[{"name":"6Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0923-3110","authenticated-orcid":false,"given":"Hartmut","family":"Koeppen","sequence":"additional","affiliation":[{"name":"2Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Piccione","sequence":"additional","affiliation":[{"name":"2Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Wilson","sequence":"additional","affiliation":[{"name":"2Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Wei","sequence":"additional","affiliation":[{"name":"2Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Yin","sequence":"additional","affiliation":[{"name":"2Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elicia","family":"Penuel","sequence":"additional","affiliation":[{"name":"2Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2024022916421630000_bib1","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","article-title":"Characterization of a human B lymphocyte-specific antigen","volume":"125","author":"Stashenko","year":"1980","journal-title":"J\u00a0Immunol"},{"issue":"suppl 5","key":"2024022916421630000_bib2","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"issue":"31","key":"2024022916421630000_bib4","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2024022916421630000_bib5","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024022916421630000_bib6","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","article-title":"Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial","volume":"98","author":"Mounier","year":"2013","journal-title":"Haematologica"},{"issue":"14","key":"2024022916421630000_bib7","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide\u00a0plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024022916421630000_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort\u00a0data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2024022916421630000_bib9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"287","key":"2024022916421630000_bib10","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"issue":"suppl 1","key":"2024022916421630000_bib11","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1182\/blood-2022-157691","article-title":"Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed\/refractory follicular lymphoma who received \u22652 prior therapies: updated results from a pivotal phase II study","volume":"140","author":"Bartlett","year":"2022","journal-title":"Blood"},{"issue":"suppl","key":"2024022916421630000_bib12","doi-asserted-by":"crossref","first-page":"e36694eb","DOI":"10.1097\/01.HS9.0000971208.36694.eb","article-title":"Mosunetuzumab demonstrates durable responses in patients with relapsed and\/or refractory follicular lymphoma who have received \u22652 prior therapies: updated analysis of a pivotal phase II study [abstract]","volume":"7","author":"Sehn","year":"2023","journal-title":"Hemasphere"},{"issue":"17","key":"2024022916421630000_bib13","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2024022916421630000_bib14","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1182\/blood-2022-157710","article-title":"SUNMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin versus rituximab in combination with gemcitabine plus oxaliplatin in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma","volume":"140","author":"Westin","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2024022916421630000_bib15","doi-asserted-by":"crossref","DOI":"10.1182\/hem.V19.6.2022610","article-title":"CELESTIMO: a randomized phase III trial examining the efficacy and safety of mosunetuzumab in combination with lenalidomide versus rituximab in combination with lenalidomide in relapsed\/refractory follicular lymphoma","volume":"19","author":"Nastoupil","year":"2022","journal-title":"Hematologist"},{"issue":"8","key":"2024022916421630000_bib16","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"2024022916421630000_bib17","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target\u00a0evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2024022916421630000_bib18","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"3","key":"2024022916421630000_bib19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3324\/haematol.2008.001024","article-title":"CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure","volume":"94","author":"Johnson","year":"2009","journal-title":"Haematologica"},{"issue":"20","key":"2024022916421630000_bib20","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":"Down-regulation of CD20 expression in B-cell\u00a0lymphoma cells after treatment with\u00a0rituximab-containing combination chemotherapies: its prevalence and clinical\u00a0significance","volume":"113","author":"Hiraga","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2024022916421630000_bib21","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/j.1349-7006.2012.02307.x","article-title":"Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment","volume":"103","author":"Miyoshi","year":"2012","journal-title":"Cancer Sci"},{"issue":"13","key":"2024022916421630000_bib22","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","article-title":"Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma","volume":"4","author":"Rushton","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2024022916421630000_bib23","first-page":"710","article-title":"Clinical significance of the loss of CD20\u00a0antigen on tumor cells in patients with\u00a0relapsed or refractory follicular lymphoma","volume":"4","author":"Michot","year":"2021","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"2024022916421630000_bib24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0378-1119(00)00598-9","article-title":"Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and beta subunit of the high-affinity IgE receptor","volume":"264","author":"Ishibashi","year":"2001","journal-title":"Gene"},{"issue":"1","key":"2024022916421630000_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/icb.2015.48","article-title":"The MS4A family: counting past 1, 2 and 3","volume":"94","author":"Eon Kuek","year":"2016","journal-title":"Immunol Cell Biol"},{"issue":"2","key":"2024022916421630000_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/j.seminhematol.2010.01.001","article-title":"CD20 as a target for therapeutic type I and II monoclonal antibodies","volume":"47","author":"Beers","year":"2010","journal-title":"Semin Hematol"},{"issue":"1","key":"2024022916421630000_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"issue":"20","key":"2024022916421630000_bib28","doi-asserted-by":"crossref","first-page":"15073","DOI":"10.1074\/jbc.M701654200","article-title":"Structural basis for recognition of CD20 by therapeutic antibody rituximab","volume":"282","author":"Du","year":"2007","journal-title":"J\u00a0Biol Chem"},{"issue":"11-12","key":"2024022916421630000_bib29","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.molimm.2009.04.009","article-title":"Structure of the Fab fragment of therapeutic antibody ofatumumab provides insights into the recognition mechanism with CD20","volume":"46","author":"Du","year":"2009","journal-title":"Mol Immunol"},{"issue":"8","key":"2024022916421630000_bib30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"2024022916421630000_bib31","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/bioinformatics\/btq057","article-title":"Fast and SNP-tolerant detection of complex variants and splicing in short reads","volume":"26","author":"Wu","year":"2010","journal-title":"Bioinformatics"},{"key":"2024022916421630000_bib32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/978-1-4939-3578-9_15","article-title":"GMAP and GSNAP for genomic sequence alignment: enhancements to speed, accuracy, and functionality","volume":"1418","author":"Wu","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"22","key":"2024022916421630000_bib33","doi-asserted-by":"crossref","first-page":"11189","DOI":"10.1093\/nar\/gks918","article-title":"LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets","volume":"40","author":"Wilm","year":"2012","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"2024022916421630000_bib34","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024022916421630000_bib35","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma","volume":"6","author":"Br\u00f6ske","year":"2022","journal-title":"Blood Adv"},{"issue":"20","key":"2024022916421630000_bib36","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.2023020400","article-title":"Alternative splicing of its 5\u2019 UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies","volume":"142","author":"Ang","year":"2023","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/9\/822\/2216707\/blood_bld-2023-022348-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/9\/822\/2216707\/blood_bld-2023-022348-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T11:42:45Z","timestamp":1709206965000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/9\/822\/506503\/Loss-of-CD20-expression-as-a-mechanism-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,2,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022348","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}